Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0483 | rifabutin

Molecular Formula C46H62N4O11
Molecular Weight 847
Structure
State solid
Clearance * 0.69 +/- 0.32 L/hr/kg
Route of elimination A mass-balance study in three healthy adult volunteers with 14C-labeled rifabutin showed that 53% of the oral dose was excreted in the urine, primarily as metabolites. About 30% of the dose is excreted in the feces.
Protein binding 0.85
Half life 45 (± 17) hours
Absorption Rifabutin is readily absorbed from the gastrointestinal tract, with an absolute bioavailability averaging 20%.

J

J04AB04 Rifabutin


[J04AB] Antibiotics


[J04A] DRUGS FOR TREATMENT OF TUBERCULOSIS


[J04] ANTIMYCOBACTERIALS


[J] Antiinfectives for systemic use

Toxicity Dose Time Species Model Method Action Positive criterion Reference
UNCOUPLING rat isolated liver mitochondria measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay increase 53


  • (7S,11S,12R,13S,14R,15R,16R,17S,18S)-2,15,17-trihydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23,32-trioxo-8,33-dioxa-24,27,29-triazaspiro[pentacyclo[23.6.1.1^{4,7}.0^{5,31}.0^{26,30}]tritriacontane-28,4'-piperidin]-1,3,5(31),9,19,21,25,29-octaen-13-yl acetate (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-6,18,20-trihydroxy-1'-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethyl-5,10,26-trioxo-3,5,9,10-tetrahydrospiro[9,4-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[1,2-d]imidazole-2,4'-piperidin (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-6-16,18,20-Tetrahydroxy-1'-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethylspiro(9,4-(epoxypentadeca(1,11,13)trienimino)-2H-furo(2',3':7,8)naphth(1,2-d)imidazole-2,4'-piperidine)-5,10,26(3H,9H)-trione,16-acetate
    (trihydroxy-1'-isobutyl-methoxy-heptamethyl-trioxo-spiro[[?]-4,4'-piperidine]yl) acetate 1,4-Dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxorifamycin XIV 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S
    4-N-isobutylspiropiperidylrifamycin S 559R069 72559-06-9
    AB01209745-01 AB01274733-01 AB01274733_02
    AB2000265 AC-19109 ATEBXHFBFRCZMA-VXTBVIBXSA-N
    Alfacid Ansamicin Ansamycin
    Ansatipin Ansatipine Antibiotic LM 427
    Assatipin BRN 3584778 C07235
    C46H62N4O11 CAS-72559-06-9 CCG-221109
    D00424 DB00615 DRG-0085
    DSSTox_CID_10773 DSSTox_GSID_33960 DSSTox_RID_79103
    HMS1571M20 HMS3259D12 HMS3715M20
    HSDB 3577 LM 427 LM-427
    LM427 LS-143839 MLS001061256
    Mycobutin Mycobutin (TN) Mycobutin;Ansamycin;LM 427;Ansatipine
    NCGC00090762-01 NCGC00090762-02 NCGC00258312-01
    Prestwick2_001109 Q1135705 RBT
    RIFABUTIN Rifabutin (JAN/USP/INN) Rifabutin [USAN:BAN:INN]
    Rifabutin [USAN:USP:INN:BAN:JAN] Rifabutina Rifabutina [Spanish]
    Rifabutine Rifabutine [French] Rifabutinum
    Rifabutinum [Latin] Rifamycin XIV, 1',4-didehydro-1-deoxy-1,4-dihydro-5'-(2-methylpropyl)-1-oxo- Rifamycin XIV, 1,4-dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxo-
    SC-18287 SCHEMBL36043 SMR001227203
    Spiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidazole-2,4'-piperidine]-5,10,26(3H,9H)-trione, 16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-heptamethyl-1'-(2-methylpropyl)-, (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-; Tox21_111012 Tox21_200758
    ZINC169621215

    DrugBank Name rifabutin
    DrugBank DB00615
    CAS Number 72559-06-9
    PubChem Compound 135398743
    KEGG Compound ID C07235
    KEGG Drug D00424
    ChEBI 45367
    PharmGKB PA451249